Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON39872
NL-OMON39872CompletedPhase 3

A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A - PROLONGATE - PEGylated rFVIII (BAX 855) in Hemophilia A

Baxter0 sites2 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Baxter
Enrollment
2
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •- Subject and/or legal representative has/have voluntarily provided signed informed consent
  • •- Subject is 12 to 65 years old at the time of screening
  • •- Subject is male with severe hemophilia A (FVIII clotting activity < 1%) as confirmed by central laboratory at screening after the appropriate washout period or a documented FVIII clotting activity <1%
  • •- Subject has been previously treated with plasma-derived FVIII concentrates or recombinant FVIII for *150 documented exposure days (EDs)
  • •- Subject is currently receiving prophylaxis or on-demand therapy with FVIII
  • •- Subject has a Karnofsky performance score of * 60 at screening (Table 6)
  • •- Subject is human immunodeficiency virus negative (HIV-); or HIV+ with stable disease and CD4+ count > 200 cells/mm3, as confirmed by central laboratory at screening
  • •- Subject is hepatitis C virus negative (HCV-) by antibody or PCR testing (if positive, antibody titer will be confirmed by PCR), as confirmed by central laboratory at screening; or HCV+ with chronic stable hepatitis
  • •- Subject is willing and able to comply with the requirements of the protocol

Exclusion Criteria

  • •- Subject has detectable FVIII inhibitory antibodies (* 0.4 BU using the Nijmegen modification of the Bethesda assay) as confirmed by central laboratory at screening
  • •- Subject has history of FVIII inhibitory antibodies (* 0.4 BU using the Nijmegen modification of the Bethesda assay or * 0.6 BU using the Bethesda assay) at any time prior to screening
  • •- Subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (eg, qualitative platelet defect or von Willebrand*s disease).
  • •- Subject has known hypersensitivity towards mouse or hamster proteins, PEG, or Tween 80
  • •- Subject has severe chronic hepatic dysfunction [eg, *5 times upper limit of normal alanine aminotransferase (ALT), as confirmed by central laboratory at screening, or a documented INR > 1.5]
  • •- Subject has severe renal impairment (serum creatinine > 2.0 mg/dL), as confirmed by central laboratory at screening
  • •- Subject has current or recent (< 30 days) use of other PEGylated drugs prior to study participation or is scheduled to use such drugs during study participation
  • •- Subject has participated in another clinical study involving an IP or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
  • •- Subject has a medical, psychiatric, or cognitive illness or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance
  • •- Subject is a family member or employee of the investigator

Investigators

Sponsor
Baxter

Similar Trials

Active, not recruiting
Not Applicable
A study of the Safety and Effectiveness of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prevention and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A (a blood clotting disorder).
EUCTR2012-003599-38-CZBaxter Innovations GmbH132
Active, not recruiting
Phase 1
A study of the Safety and Effectiveness of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prevention and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A (a blood clotting disorder).
EUCTR2012-003599-38-GBBaxter Innovations GmbH138
Active, not recruiting
Not Applicable
A study of the Safety and Effectiveness of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prevention and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A (a blood clotting disorder).
EUCTR2012-003599-38-BGBaxter Innovations GmbH132
Active, not recruiting
Not Applicable
A study of the Safety and Effectiveness of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prevention and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A (a blood clotting disorder).
EUCTR2012-003599-38-PLBaxter Innovations GmbH132
Active, not recruiting
Phase 1
A study of the Safety and Effectiveness of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prevention and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A (a blood clotting disorder).Severe hemophilia A (FVIII <1%)MedDRA version: 16.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850
EUCTR2012-003599-38-HUBaxter Innovations GmbH138